Navigation Links
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Date:6/26/2008

bination with conventional chemotherapy regimes, as well as compare its efficacy with other anti-angiogenesis drugs, such as Avastin.

The Company is actively seeking potential partners for the further clinical development of Angiolix, a drug which holds great promise as an anti-vascular cancer therapy.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject t
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
2. A Perfect Storm Threatens Patient Access to Specialty Medical Care
3. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
4. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
5. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
6. AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
9. Scientists call for more access to biotech crop data
10. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
11. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... -- Naurex Inc., a biopharmaceutical company leveraging its unique ... central nervous system, today announced that Norbert Riedel ... at the 33 rd annual J.P. Morgan Healthcare ... p.m. PST on Tuesday, January 13, 2015, at the ... About Naurex Inc. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , ROCKVILLE, Md., Nov. 30 Novavax, Inc. (Nasdaq: NVAX ... be presenting at the 21st Annual Health Care Conference 2009 on ... York Palace, New York. Novavax will provide an overview of ... A link to the live audio only presentation can be ...
... , CHANGCHUN, China ... Inc. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharmaceuticals, or ,the ... Northeastern China, today announced it has,completed preparation for distribution ... The Chinese government recently formalized the ...
... ... (Nasdaq and MTA: CTIC) announced today that its new ... stronger anti-tumor potency and activity compared to currently available ... cisplatin-resistance in cancer cell lines. The results were ...
Cached Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... release is available in German . Plants, ... The early detection of pathogens and the subsequent immune response, ... shield. However, the pathogens that cause plant diseases have their ... wall reaction in plants. "One particularly ingenious attacker, powdery mildew, ...
... The scientific equivalent of searching for a needle in ... for potential new medicines for Parkinson,s Disease and other ... American Chemical Society,s award-winning " Global Challenges/Chemistry Solutions " ... 390,000 chemical compounds. Finally, they located one that blocks ...
... children to stop slouching for ages. It turns out ... only makes a bad impression, but can actually make you ... professor of management organization at the USC Marshall School of ... Rotman School of Management at the University of Toronto, adopting ...
Cached Biology News:TUM researchers discover a new switch in resistance to plant diseases 2Your mother was right: Study shows good posture makes you tougher 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: